Peritoneal dialysis and CAPD are not effective in removing ofloxacin from the body. Cases of hypoglycaemic coma have been reported. Preclinical data from conventional genotoxicity studies reveal no special hazard to humans, carcinogen potential has not been investigated.Ofloxacin has no effect on fertility, peri- or postnatal development, and therapeutic doses did not lead to any teratogenic or other embryotoxic effects in animals. • Gonococcal urethritis and cervicitis due to susceptible In the following indications, ofloxacin should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections: Animal studies have shown damage to the joint cartilage in immature animals but no teratogenic effects (see section 5.3). Repeated evaluation of the patient's condition is essential and periodic Photosensitisation has been reported with ofloxacin (see section 4.8). Therefore if ofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored.In patients treated with ofloxacin, determination of opiates or porphyrin levels in urine may give false-positive results. Coagulation tests should, therefore, be monitored in patients treated with vitamin K antagonists because of a possible increase in the effect of coumarin derivatives (see section 4.4).Ofloxacin may cause a slight increase in plasma glibenclamide levels when administered concurrently, it is therefore recommended that patients treated concomitantly with ofloxacin and glibenclamide be monitored particularly closely. Patients with glucose-6-phosphate-dehydrogenase deficiency. The peak plasma concentration after a single oral dose of 200 mg averaged 2.6 µg/ml and was reached within one hour. warfarin), coagulation tests should be monitored when these drugs are given concomitantly (see section 4.5).Fluoroquinolones, including ofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. 25%. The peak plasma concentration after a single oral dose of 200mg averaged 2.6 µg/ml and was reached within one hour. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.The most important signs to be expected following acute overdose are CNS symptoms such as confusion, dizziness, impairment of consciousness and convulsive seizures increases in QT interval as well as gastrointestinal reactions such as nausea and mucosal erosions.CNS effects including confusional state, convulsion, hallucination, and tremor have been observed in post marketing experience.In the case of overdose steps to remove any unabsorbed ofloxacin e.g. The plasma elimination half-life was 5.7 to 7.0 hours and was not dose related. The proposed mechanism is a competition or inhibition for active transport at the renal tubular excretion. Antacids may be used for protection of gastric mucosa. However, a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, nonsteroidal anti-inflammatory drugs, or other agents, which lower the seizure threshold.In case of convulsive seizures, treatment with ofloxacin should be discontinued.Probenecid decreased the total clearance of ofloxacin by 24%, and increased AUC by 16%. Follow the directions on the prescription label. Ofloxacin may cause a slight increase in plasma glibenclamide levels when administered concurrently, it is therefore recommended that patients treated concomitantly with ofloxacin and glibenclamide be monitored particularly closely. However, like some other quinolones Ofloxacin is phototoxic in animals at exposure in the human therapeutic range. How should I use this medicine? These effects may be enhanced by alcohol.The information given below is based on data from clinical studies and on extensive post marketing experience.Hypoglycaemia in diabetics treated with hypoglycaemic agents (see Section 4.4),Psychotic disorder and depression with self-endangering behaviour including suicidal ideation or suicide attempt (see Section 4.4),Extra-pyramidal symptoms or other disorders of muscular coordinationVentricular arrhythmias and torsades de pointes (reported predominantly in patients with risk factors for QT prolongation), ECG QT prolonged (see section 4.4 and 4.9)Hepatic enzymes increased (ALAT, ASAT, LDH, gamma-GT and/or alkaline phosphatase), Severe liver injury, including cases with acute liver failure, sometimes fatal, have been reported with ofloxacin, primarily in patients with underlying liver disorders (see section 4.4).Vasculitis, which can lead in exceptional cases to skin necrosis Tendon rupture (e.g.